Patents by Inventor Matthew Robert Sender
Matthew Robert Sender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240325392Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.Type: ApplicationFiled: February 9, 2024Publication date: October 3, 2024Inventors: Peiling CHEN, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Joseph Paul MARINO, JR., Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG
-
Publication number: 20240300965Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: ApplicationFiled: April 25, 2024Publication date: September 12, 2024Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Emst Neipp, Vipulkumar Kantibhai Patel
-
Patent number: 11999746Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: GrantFiled: July 29, 2019Date of Patent: June 4, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
-
Patent number: 11260049Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: September 20, 2017Date of Patent: March 1, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITEDInventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Peng Li, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm
-
Patent number: 11229623Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: February 21, 2020Date of Patent: January 25, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITEDInventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
-
Publication number: 20210299113Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: ApplicationFiled: September 20, 2017Publication date: September 30, 2021Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Peng LI, Jay M. MATTHEWS, John Jeffrey McATEE, Joseph E. PERO, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM
-
Publication number: 20200261411Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: ApplicationFiled: February 21, 2020Publication date: August 20, 2020Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Linda S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jaclyn R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
-
Patent number: 10588891Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: September 20, 2017Date of Patent: March 17, 2020Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
-
Publication number: 20200055863Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: ApplicationFiled: July 29, 2019Publication date: February 20, 2020Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
-
Patent number: 10428078Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: GrantFiled: September 27, 2018Date of Patent: October 1, 2019Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
-
Publication number: 20190216774Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: ApplicationFiled: September 20, 2017Publication date: July 18, 2019Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Lisa S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jacyln R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
-
Publication number: 20190023715Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: ApplicationFiled: September 27, 2018Publication date: January 24, 2019Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
-
Patent number: 10125141Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: GrantFiled: July 21, 2015Date of Patent: November 13, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel